Cells require the ability to detect and respond to stimuli in their surroundings, including to endogenous metabolites, exogenous nutrients, and environmental irritants. The proteins that are responsible for this process are called chemosensors and are involved in regulating diverse biological processes involved in pain sensation, dietary preference, and metabolic control. Because chemosensors transmit external environmental information into the cell, nearly all chemosensors are structurally-complex membrane proteins that span the cell's plasma membrane multiple times, such as ion channels, transporters, and G protein-coupled receptors. However, because most chemosensors are difficult to express, purify, and solubilize, structural and functional information about them has been exceptionally difficult to obtain. The goal of this Phase 2 proposal is to engineer chemosensors with increased surface expression and increased stability in solution and to map ligand and drug binding sites on these chemosensors.

Public Health Relevance

This project will contribute to human health by providing tools that will enable new small molecules and therapeutic MAbs to be developed against specific chemosensor targets. These targets are involved in the transmission of pain, cancer, and metabolic disorders, yet there are currently no FDA-approved drugs against any of our target protein families. The lack of therapeutic drugs and antibodies against these targets, and most chemosensors in general, reflects their conformational complexity and the lack of tools that have been able to manipulate and engineer these proteins for commercial purposes.

National Institute of Health (NIH)
National Institute on Deafness and Other Communication Disorders (NIDCD)
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-ETTN-P (11))
Program Officer
Sullivan, Susan L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Integral Molecular
United States
Zip Code
Tucker, David F; Sullivan, Jonathan T; Mattia, Kimberly-Anne et al. (2018) Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles. Proc Natl Acad Sci U S A 115:E4990-E4999
Thomas, Anu; Sulli, Chidananda; Davidson, Edgar et al. (2017) The Bitter Taste Receptor TAS2R16 Achieves High Specificity and Accommodates Diverse Glycoside Ligands by using a Two-faced Binding Pocket. Sci Rep 7:7753
Chen, Derek E; Willick, Darryl L; Ruckel, Joseph B et al. (2015) Principal component analysis of binding energies for single-point mutants of hT2R16 bound to an agonist correlate with experimental mutant cell response. J Comput Biol 22:37-53
Campbell, Michael C; Ranciaro, Alessia; Zinshteyn, Daniel et al. (2014) Origin and differential selection of allelic variation at TAS2R16 associated with salicin bitter taste sensitivity in Africa. Mol Biol Evol 31:288-302
Greene, Tiffani A; Alarcon, Suzanne; Thomas, Anu et al. (2011) Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLoS One 6:e20123